Dystonia in Parkinson's Disease:Clinical & Pharmacological Features
Ann Neurol 23:73-78, Poewe,W.H.,et al, 1988
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
Duodenal and Gastric Delivery of Levodopa in Parkinsonism
Ann Neurol 23:589-595, Kurlan,R.,et al, 1988
Long-Term Duodenal Infusion of Levodopa for Motor Fluctuations in Parkinsonism
Ann Neurol 24:87-89, Sage,J.I.,et al, 1988
Controlled-Release Carbidopa/Levodopa (CR4-Sinemet) in Parkinson's Disease Pts With & Without Motor Fluctuations
Neurol 38:1143-1146, Goetz,C.G.,et al, 1988
Treatment of Chronic Parkinson's Disease with Controlled-Release Carbidopa/Levodopa
Arch Neurol 45:861-864, Hutton,J.T.,et al, 1988
Uneven Pattern of Dopamine Loss in the Striatum with Idiopathic Parkinson's Disease, Pathophysiologic & Clinical Implications
NEJM 318:876-880, Kish,S.J., 1988
Treatment of Restless Legs Syndrome & Periodic Movements During Sleep with L-Dopa:A Double-Blind, Controlled Study
Neurol 38:1845-1848, Brodeur,C.,et al, 1988
Does Levodopa Aggravate Parkinson's Disease
Neurol 38:1410-1416, Blin,J.,et al, 1988
Possible Benefit of GR43175, A Novel 5-HT1-Like Receptor Agonist for the Acute Treatment of Severe Migraine
Lancet 1:1309-1311, Doenicke,A.,et al, 1988
Cardiac Arrhythmias
In Handbook of Parkinson's Disease, W. C. Koller (ed) , Marcal Dekker, Inc, New York, 1987, p 151., , 1987
Classification of Parkinsonism
in Handbook of Parkinson's Disease, Marcel Dekker, Inc, New York, Ch 3, p 61., Koller,W.C., 1987
Progression of Parkinson's Disease Without Levodopa
Neurol 37:695-698, Coetz,C.G.,et al, 1987
Controlled-Release Levodopa/Carbidopa. I. Sinemet CR3 Treatment of Response Fluctuations in Parkinson's Disease
Neurol 37:233-241, Cedarbaum,J.M.,et al, 1987
Controlled Release Levodopa Treatment of Motor Fluctuations in Parkinson's Disease
JNNP 50:194-198, Juncos,J.L.,et al, 1987
Factors that Influence the Occurrence of Response Variations in Parkinson's Disease
Ann Neurol 22:4-7, deJong,G.J.,et al, 1987
Multi-Center Study of Parkinson Mortality with Early Versus Later Dopa Treatment
Ann Neurol 22:8-12, Diamond,S.G.,et al, 1987
Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987
Forms of Dystonia in Patients with Parkinson's Disease
Neurol 37:1009-1011, Kidron,D.&Melamed,E., 1987
Parkinson's Disease & Motor Fluctuations:Long-Acting Carbidopa. Levodopa (CR-4-Sinemet)
Neurol 37:875-878, Goetz,C.G.,et al, 1987
Controlled-Release Levodopa/Carbidopa. II. Sinemet CR4 Treatment of Response Fluctuations in Parkinson's Disease
Neurol 37:1607-1612, Cedarbaum,J.M.,et al, 1987
Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
Arch Neurol 44:1010-1012, Juncos,J.L.,et al, 1987
Dietary Influence on the Antiparkinsonian Response to Levodopa
Arch Neurol 44:1003-1005, Juncos,J.L.,et al, 1987
Levodopa Methyl Ester Treatment of Parkinson's Disease
Neurol 37:1242-1245, Juncos,J.L.,et al, 1987
Progressive Myoclonus Epilepsies:Specific Causes & Diagnosis
NEJM 315:296-305, Berkovic,S.F.,et al, 1986
Hereditary Dystonia-Parkinsonism Syndrome of Juvenile Onset
Neurol 36:1424-1428, Nygaard,T.C.&Duvoisin,R.C., 1986
Initiation of Levodopa Therapy in Parkinsonisn Patients Should be Delayed Until the Advanced Stages of the Disease
Arch Neurol 43:402-407, Melamen,E., 1986
Modification of Parkinson's Disease by Long-Term Levodopa Treatment
Arch Neurol 43:405-407, Markham,C.H.&Diamond,S.G., 1986
Painful Parkinson's Disease
Lancet 1:1366-1369, Quinn,N.P.,et al, 1986
Levodopa in Restless Legs
Lancet 2:426-427, vonScheele,C., 1986
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
A Neuroleptic Malignantlike Syndrome Due to Levodopa Therapy Withdrawal
JAMA 254:2792-2795, Friedman,J.H.,et al, 1985
L-Dopa-Induced Respiratory Disturbance in Parkinson's Disease Suppressed by Tiapride
Neurol 35:235-237, DeKeyser,J.,et al, 1985
Low Dosages of Bromocriptine Added to Levodopa in Parkinson's Disease
Neurol 35:199-206, Maier,M.M.,et al, 1985
Hyperthermia after Discontinuance of Levodopa & Bromocriptine Therapy:Impaired Dopamine Receptors a Possible Cause
Neurol 35:258-261, Figa-Talamanca,L.,et al, 1985
Development of Malignant Melanoma after Levodopa Therapy for Parkinson's Disease, Report of Case & Review
Am J Med 79:119-121, Kochar,A.S., 1985
Levodopa & Melanoma:Three Cases & Review of Literature
JNNP 48:585-588, Rampen,F.H.J., 1985
Response Variations in the Treatment of Parkinson's Disease
Neurol 34:1507-1509, deJong,G.J.,et al, 1984
Pathologic Laughing & Crying Treated with Levodopa
Arch Neurol 41:1095-1096, Udaka,F.,et al, 1984
Chronic Low-Dose Levodopa Therapy in Parkinson's Disease:An Argument for Delaying Levodopa Therapy
Neurol 34:991-996, Rajput,A.H.,et al, 1984
Fatal Hyperpyrexia After Withdrawal of Levodopa
Neurol 34:249-251, Sechi,G.P.,et al, 1984
Skin Rash Associated with Sinemet 25/100
NEJM 309:1387-1388, Goetz,C.G., 1983
Alternate Day Levodopa Therapy in Parkinsonism
Neurol 32:324-326, Koller,W.C., 1982
False-Negative Results With Levodopa For Early Detection Of Huntington's Disease
NEJM 307:561-562, Myers,R.H.,et al, 1982
Meige's Syndrome During Long-term Dopaminergic Therapy in Parkinson's Disease
Arch Neurol 39:451-452, Weiner,W.J.,et al, 1982
Dystonia Musculorum Deformans, Implications of Therapeutic Response to Levodopa & Carbamazepine
Arch Neurol 39:376-377, Garg,B.P., 1982
Neurotoxicity of the Pyrimidine Synthesis Inhibitor N-Phosphonoacetyl-L-Aspartate
Ann Neurol 12:175-183, Wiley,R.G.,et al, 1982
Drug-induced Asterixis in Parkinson Disease
Neurol 32:553-555, Glantz,R.,et al, 1982
Stroke Due to Treatment with L-Asparginase in an Adult
NEJM 307:1643, Lederman,G.S., 1982
Lisuride Combined with Levodopa in Advanced Parkinson Disease
Neurol 31:1466-1469, Lieberman,A.N.,et al, 1981